Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

The latest buyout Novo Nordisk is trying to pull off is putting it in a direct confrontation with another beaten-down ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

The lawsuit says Novo Nordisk’s offer for drug startup Metsera isn’t reasonably likely to be completed.

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US ...

Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s growth are falling, too. By Eshe Nelson The success of Novo Nordisk, the ...

Berenberg Bank just upgraded Novo Nordisk to a buy. The banker believes investor expectations have reset and it's now possible Novo Nordisk has fallen enough to bounce again. Novo Nordisk created the ...

Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy, just announced plans to cut 11% of its workforce as competitors like Eli Lilly continue to ...

Novo Nordisk (NYSE: NVO)-- the original Ozempic stock-- is getting a boost from a Financial Times report this morning highlighting positive results from two weight loss trials using increased dosages ...